Nutriband Signs Agreement Brand Institute For AVERSA Fentanyl, Plans To Commercialize Abuse-Deterrent Opioid Patch

Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system.

Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development.

ORLANDO, Fla., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that through its 4P Therapeutics subsidiary, it has signed an agreement with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development services to develop the worldwide commercial brand name and visual identity for its lead product, an abuse deterrent fentanyl transdermal system. This product utilizes Nutriband's AVERSA™ abuse deterrent transdermal technology and has the development name AVERSA™ FENTANYL.

AVERSA™ FENTANYL has the potential to be the world's first abuse-deterrent opioid patch designed to deter abuse and misuse and reduce the risk of accidental exposure of opioids such as fentanyl.